Skip to content
value.today

Saladax Biomedical Inc

Total raised
$31 M
2 rounds on record
Latest round
$23 M
Feb 2013
First round on record
Sep 2009
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Saladax Biomedical Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2013$23 MNo. 2$10 to $50 million

Saladax Biomedical Inc: Raise no. 2, Feb 2013

Investors in this round

7 investors had bought by the notice of Sep 10, 2013: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$23 M of $23 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Series D Preferred Stock
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Adrienne Choma · Executive Officer, Director
  • Kevin J. Harter · Executive Officer, Director
  • Salvatore J. Salamone · Executive Officer, Director
  • Edward L. Erickson · Director
  • Enrico J. Petrillo · Director
  • Greg L. Critchfield · Director · Chairman of the Board
  • James J. Hensel · Director
  • Joel J. Gross · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Some proceeds may be used for general working capital including compensation to those named in Item 3.”

Signed by Kevin M. Harter, Ceo. Source: SEC Form D, newest notice filed Sep 10, 2013. Read the notice at the SEC.

equitySEC
Sep 2009$8 MNo. 1$2 to $10 million

Saladax Biomedical Inc: Raise no. 1, Sep 2009

Investors in this round

62 investors had bought by the notice of Oct 5, 2009: 62 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $9 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Adrienne Choma · Executive Officer, Director
  • Salvatore J. Salamone · Executive Officer, Director
  • Enrico J. Petrillo · Director
  • James J. Hensel · Director
  • Joel J. Gross · Director
  • Kevin J. Harter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Toni L. Klich, Director, Finance and Administration. Source: SEC Form D, newest notice filed Oct 5, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Saladax Biomedical Inc chose not to state its revenue in its newest notice of a funding round (Sep 2013).

    SEC Form D · Sep 2013

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Sep 2013

That is all the official record says: Saladax Biomedical Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Saladax Biomedical Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 62 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Saladax Biomedical Inc
NameRoleNamed in
Adrienne ChomaExecutive officerSep 2013
Kevin J. HarterExecutive officerSep 2013
Salvatore J. SalamoneExecutive officerSep 2013
Adrienne ChomaDirectorSep 2013
Edward L. EricksonDirectorSep 2013
Enrico J. PetrilloDirectorSep 2013
Greg L. CritchfieldChairman of the BoardSep 2013
James J. HenselDirectorSep 2013
Joel J. GrossDirectorSep 2013
Kevin J. HarterDirectorSep 2013
Salvatore J. SalamoneDirectorSep 2013